메뉴 건너뛰기




Volumn 8, Issue 3, 2011, Pages 127-128

Hematology: Curing CML with imatinib-a dream come true?

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB; PEGINTERFERON ALPHA;

EID: 79952443657     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.17     Document Type: Article
Times cited : (30)

References (10)
  • 2
    • 78049528573 scopus 로고    scopus 로고
    • Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre stop imatinib (sTiM) trial
    • Mahon, F. X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (sTiM) trial. Lancet Oncol. 11, 1029-1035 (2010).
    • (2010) Lancet Oncol. , vol.11 , pp. 1029-1035
    • Mahon, F.X.1
  • 3
    • 77958012952 scopus 로고    scopus 로고
    • Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DnA PCR
    • Ross, D. M. et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DnA PCR. Leukemia 24, 1719-1724 (2010).
    • (2010) Leukemia , vol.24 , pp. 1719-1724
    • Ross, D.M.1
  • 4
    • 0032211172 scopus 로고    scopus 로고
    • The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease
    • Bose, S., Deininger, M., Gora-Tybor, J., Goldman, J. M. & Melo, J. V. The presence of BCR-ABL fusion genes in leukocytes of normal individuals: implications for the assessment of minimal residual disease. Blood 92, 3362-3367 (1998). (Pubitemid 28492345)
    • (1998) Blood , vol.92 , Issue.9 , pp. 3362-3367
    • Bose, S.1    Deininger, M.2    Gora-Tybor, J.3    Goldman, J.M.4    Melo, J.V.5
  • 5
    • 77951632041 scopus 로고    scopus 로고
    • Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase
    • Goldman, J. M. et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J. Clin. Oncol. 28, 1888-1895 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , pp. 1888-1895
    • Goldman, J.M.1
  • 7
    • 77950396947 scopus 로고    scopus 로고
    • Significant higher rates of undetectable molecular residual disease and molecular responses with pegylated form of interferon a2a in combination with imatinib (iM) for the treatment of newly diagnosed chronic phase (CP) chronic myeloid leukaemia (CML) patients (pts): Confirmatory results at 18 months of part 1 of the spirit phase ii randomized trial of the French CML Group (Fi LMC) [abstract]
    • Guilhot, F. et al. significant higher rates of undetectable molecular residual disease and molecular responses with pegylated form of interferon a2a in combination with imatinib (iM) for the treatment of newly diagnosed chronic phase (CP) chronic myeloid leukaemia (CML) patients (pts): confirmatory results at 18 months of part 1 of the spirit phase ii randomized trial of the French CML Group (Fi LMC) [abstract]. Blood 114, a340 (2009).
    • (2009) Blood , vol.114
    • Guilhot, F.1
  • 9
    • 77958595179 scopus 로고    scopus 로고
    • Long-term prognostic significance of early molecular response to matinib in newly diagnosed chronic myeloid leukemia: An analysis from the international Randomized study of interferon and sTi571 (iRis)
    • Hughes, T. P et al. Long-term prognostic significance of early molecular response to matinib in newly diagnosed chronic myeloid leukemia: an analysis from the international Randomized study of interferon and sTi571 (iRis). Blood 116, 3758-3765 (2010).
    • (2010) Blood , vol.116 , pp. 3758-3765
    • Hughes, T.P.1
  • 10
    • 34548225514 scopus 로고    scopus 로고
    • Minimum viable population size: A meta-analysis of 30 years of published estimates
    • DOI 10.1016/j.biocon.2007.06.011, PII S0006320707002534
    • Traill, L. W., Bradshaw, C. J. & Brook, B. W. Minimum viable population size: A meta-analysis of 30 years of published estimates. Biological Conservation 139, 159-166 (2007). (Pubitemid 47320616)
    • (2007) Biological Conservation , vol.139 , Issue.1-2 , pp. 159-166
    • Traill, L.W.1    Bradshaw, C.J.A.2    Brook, B.W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.